Abstract
Opioid addiction (OA) has strong heritability, yet few genetic variant associations have been robustly identified. Only rs1799971, the A118G variant in OPRM1, has been identified as a genome-wide significant association with OA and independently replicated. We applied genomic structural equation modeling to conduct a GWAS of the new Genetics of Opioid Addiction Consortium (GENOA) data and published studies (Psychiatric Genomics Consortium, Million Veteran Program, and Partners Health), comprising 23,367 cases and effective sample size of 88,114 individuals of European ancestry. Genetic correlations among the various OA phenotypes were uniformly high (rg > 0.9). We observed the strongest evidence to date for OPRM1: lead SNP rs9478500 (p=2.56×10−9). Gene-based analyses identified novel genome-wide significant associations with PPP6C and FURIN. Variants within these loci appear to be pleiotropic for addiction and related traits.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The National Institute on Drug Abuse: R01DA044014, R01DA038632, R33DA027486 (EOJ, NG, DBH); K01DA036751 (RCC), U10DA13043 (WHB), R01DA04401 (RCC, WHB) The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (OL, MR, MJK), The Clinical and Translational Science Award UL1RR024143 from the National Center for Advancing Translational Sciences of the NIH (MJK). U01AA008401 (LW, DL, KB, TF, AA, BP, HE); Pennsylvania State Department of Health Tobacco Settlement non-formulary grant Pharmacogenetics of Opioid Use Disorder (RCC, WHB). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from: GTEx Analysis v8 of the GTEx Portal on 05/18/21 and/or dbGaP accession number phs000424.v8.p2 on 02/17/2021.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All contributing cohorts obtained necessary patient/participant consent and appropriate institutional IRB approval received. Meta-analyses of these genetic data is approved under RTI International IRB review (IRB ID: CR00000710 for 14107).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵** Recently deceased.
Data Availability
The GWAS summary statistics generated and/or analyzed during the current study will be made available via dbGAP; the dbGaP accession assigned to the UHS is phs000454.v1.p1. The website is https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000454.v1.p1
